OncoSec Medical Inc (ONCS) Stock
ONCS is no longer traded. OncoSec Medical was delisted from the Nasdaq in August 2023.
Prices on this page are historical; the last trade was August 21, 2023 at $0.00.
OncoSec Medical stock price history
ONCS final trading statistics
- Final close
- $0.00
- Final trading day
- Aug 21, 2023
- Market cap at delisting
- $1.65M
- Shares outstanding
- 5.96M
- Final 52-week range
- $0.00 – $6.50
- Avg. volume (final 3 mo.)
- 1,442,526
- All-time high (split-adj.)
- $8272.00 · May 2011
- All-time low (split-adj.)
- $0.00 · Aug 2023
- Return since IPO
- -100.0%
- Beta
- 2.00
- Book value / share
- -$1.85
- Price / book
- -0.00
OncoSec Medical annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $0.00 | -$34.2M | -$19.14 |
| FY2021 | $0.00 | -$45.2M | -$31.46 |
| FY2020 | $0.00 | -$42.3M | -$63.58 |
| FY2019 | $0.00 | -$30.3M | -$94.82 |
| FY2018 | $0.00 | -$39.1M | -$205.48 |
Last five fiscal years reported before the delisting; fiscal year ending July. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About OncoSec Medical Inc
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.
OncoSec Medical stock FAQ
What happened to OncoSec Medical stock?
OncoSec Medical stock was delisted from the Nasdaq. Its final close was $0.00 on August 21, 2023.
Is ONCS stock still trading?
No. ONCS was delisted from the Nasdaq in August 2023 and no longer trades on a U.S. exchange.
What was the last price of ONCS stock?
ONCS closed at $0.00 on its final trading day, August 21, 2023, for a market value of about $1.65M.
What were OncoSec Medical's revenue and earnings in its last full fiscal year?
OncoSec Medical reported revenue of $0.00 and net income of -$34.2M in fiscal 2022, its last full year as a public company.
When did OncoSec Medical go public?
OncoSec Medical Inc stock began trading on March 31, 2011.